XPH Crowded With Sellers

In trading on Tuesday, shares of the SPDR S&P Pharmaceuticals ETF ( XPH) entered into oversold territory, changing hands as low as $88.19 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In the case of SPDR S&P Pharmaceuticals, the RSI reading has hit 28.6 — by comparison, the RSI reading for the S&P 500 is currently 44.7.

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

A bullish investor could look at XPH's 28.6 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.

Looking at a chart of one year performance (below), XPH's low point in its 52 week range is $62.43 per share, with $102.80 as the 52 week high point — that compares with a last trade of $88.17. SPDR S&P Pharmaceuticals shares are currently trading off about 1.4% on the day.

SPDR S&P Pharmaceuticals 1 Year Performance Chart

If you liked this article you might like

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks Slide as Health Care Sector Weighs on Wall Street

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Drugmakers Suffer After Trump Tweet

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington